
New findings on spinal muscular atrophy
Researchers investigate the impact on the immune system.

TWINCORE was founded in 2008 by the Helmholtz Centre for Infection Research and the Hannover Medical School. We combine the expertise of medical professionals and scientists from a wide range of disciplines to find answers to the pressing questions in infection research. Our focus: translational research – the bridge between basic science and clinical application.

Researchers investigate the impact on the immune system.

How bacteria develop resistance to antisense antibiotics - and how future therapies can be designed to reduce the risk of resistance

A team of researchers from Hamburg, Berlin, Göttingen and Hannover has provided evidence of possible cross-protection offered by an already authorised Zaire Ebola virus vaccine.
We conduct translational infection research to improve the prevention, diagnosis and treatment of infectious diseases in humans. We focus on three areas that characterize our research work. Find out here how we proceed and what results we achieve.
Under the leadership of our best scientists, various labs are working on different projects within our research topics.
Karhan C, Sake S, Urbanek-Quaing M, Bergamo D, Rückert J, Huang J, Grethe C, Gunesch A, Kühnel A, Reinecke B, Fischer N, Schulz T, Pietschmann T, Hirsch A
Chuprikova L, Chong L, Ruff S, Seitz S, Lauber C
Hartmann O, Preusse M, Heroven A, Felgner S, Gür M, Kordes A, Wolff Bengtsen V, Roghanian M, Zhao X, Müsken M, Gomez N, Häussler S
In this project, antibodies that help to ward off infections are being investigated in more detail. The aim is to find characteristics that have a protective effect against certain pathogens by comparing different antibody profiles in infections and vaccinations.
The project is researching how the effect of monoclonal antibodies can be improved. These antibodies are already being used successfully against viruses. The aim is to optimize the so-called Fc effector functions in order to fight infections even more effectively.
We develop high-throughput screening assays to identify antiviral molecules against RSV and SARS-CoV-2. We use compound libraries, investigate new mechanisms of action and strive for innovative therapies.
The CoViPa consortium uses computer-assisted high-throughput virus discovery and evolutionary analyses to identify RNA viruses with high spillover risk and potential animal host reservoirs and to investigate new pathogenicity factors.
There are currently no events.

